London-based BenevolentAI, which is developing AI tech for drug discovery and more, announces $115M funding round at a $2.1B post-money valuation
Context & Ripple Effects
In 2018, BenevolentAI's $115M round at a $2.1B post-money valuation made it one of Europe's largest AI bets, anchoring what would become a dense London cluster for AI in biomedicine. The related coverage shows that cluster maturing: Causaly later raised a $60M Series B for biomedical research AI, and Huma Therapeutics reached a near-$1B valuation on an $80M Series D.
The comparison point is Lila Sciences, which in 2025 raised the identical $115M figure at a $1.3B valuation as part of a $550M total — meaning the same cheque now buys a larger stake than it did when BenevolentAI set the benchmark seven years earlier.
First-order effects
- BenevolentAI instantly becomes one of Europe's most valuable AI startups, giving London a flagship for applying machine learning to drug discovery rather than consumer apps.
- Investors backing the round establish a ~$2B reference price for AI-native drug discovery platforms, which later entrants are priced against.
Second-order effects
- Specialist rivals emerge in the same lane — Causaly in biomedical research, Enveda combining AI with natural compounds — forcing differentiation by data and therapeutic focus rather than the 'AI for drugs' label alone.
- The category's fundraising cadence normalizes nine-figure rounds for pre-revenue science companies, pulling generalist capital toward deep-tech biotech alongside sector funds.
Third-order effects
- If the pattern holds, AI drug discovery consolidates from a single-flagship story into a standing venture category where each wave is valued more conservatively per dollar raised — Lila's $115M at $1.3B versus BenevolentAI's $115M at $2.1B suggests the market learned to discount headline AI premiums.
- London's position as the hub for this category reinforces its broader claim as Europe's leading tech centre, with biomedical AI joining fintech and infrastructure as pillars of the city's startup economy.
The trend: AI-driven drug discovery has evolved from one-off mega-bets like BenevolentAI into a recurring, increasingly valuation-disciplined venture category clustered in London.